Pharming Group NV (PHAR) Stock Analysis

Pharming Group NV (PHAR) is a publicly traded company in the HEALTHCARE sector. It trades at $12.28, carries a market capitalization of $923.78M, a price-to-earnings ratio of 68.84. This page summarizes the public market data, fundamentals, and frequently asked questions for PHAR, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Pharming Group NV currently has a Neutral sentiment score of 0.15.

About Pharming Group NV

Pharming Group NV is a leading specialty pharmaceutical company based in Leiden, the Netherlands, committed to developing innovative therapies for rare diseases and unmet medical needs worldwide. Utilizing its proprietary recombinant DNA technology, Pharming produces safe and effective treatments with a significant focus on improving patient outcomes. The company's strong presence in the United States and Europe underscores its dedication to addressing critical health challenges, providing ac...

GNG Research Analysis

GNG Research scores Pharming Group NV (PHAR) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for PHAR.

Frequently Asked Questions

Does PHAR pay dividends?

Pharming Group NV (PHAR) does not currently pay a regular dividend.

What is PHAR's P/E ratio?

Pharming Group NV has a price-to-earnings (P/E) ratio of 68.84.

What is PHAR's market cap?

Pharming Group NV (PHAR) has a market capitalization of $923.78M with a current stock price of $12.28.